SunTrust Robinson Thinks Tetraphase’s Stock is Going to Recover

By Jason Carr

SunTrust Robinson analyst Edward Nash reiterated a Buy rating on Tetraphase (NASDAQ: TTPH) today and set a price target of $10. The company’s shares opened today at $2.51, close to its 52-week low of $2.10.

According to TipRanks.com, Nash is a 5-star analyst with an average return of 19.4% and a 47.1% success rate. Nash covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Achillion Pharmaceuticals, and Melinta Therapeutics Inc.

Currently, the analyst consensus on Tetraphase is Strong Buy and the average price target is $7.50, representing a 198.8% upside.

In a report issued on February 6, H.C. Wainwright also maintained a Buy rating on the stock with a $17 price target.

The company has a one-year high of $9.93 and a one-year low of $2.10. Currently, Tetraphase has an average volume of 476.5K.

Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TTPH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel antibiotics for serious and life-threatening bacterial infections. It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.